Assessment of Ability Related to Vision

Reproducibility and Clinical Usefulness of AARV (Assessment of Ability Related to Vision)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01027312

Acronym

AARV

Enrollment

121

Registered

2009-12-07

Start date

2008-02-29

Completion date

2010-08-31

Last updated

2016-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Keywords

Glaucoma, quality of life, daily living activities, visual fields, contrast sensitivity

Brief summary

To determine the clinical usefulness of a refined third-generation instrument - The Assessment of Ability Related to Vision (AARV) in establishing the amount of disability, charting the detrimental effects of progressive disease and establishing the beneficial effects of treatment

Detailed description

This research study is designed to test the usefulness and repeatability of testing how much disability is caused by vision loss due to glaucoma. We are recruiting 100 patients with glaucoma and 20 healthy (have no eye disease) individuals to be enrolled in this study. The healthy study participants will be enrolled in order to describe how a healthy individual will perform on the test designed to assess one's performance when completing ten activities of daily living. Clinical testing will be conducted by binocular and monocular visual fields, contrast sensitivity and visual acuity. The NEI-VFQ 15 Quality of Life Questionnaire will be used to measure patients perception of how well they are doing.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* All patients 18 yrs of age and older * must understand and respond to spoken English and be fully literate.

Exclusion criteria

* Patients with significant neurological problems (like Parkinson's disease), motor problems (like arthritis) or other significant illnesses that may prevent them from completing the testing involved in the study (like advanced heart failure). * Patients who have received training related to low vision.

Design outcomes

Primary

Measure	Time frame
the reproducibility of AARV, and its relationship to standard clinical tests	Day 1, 1 week, 6 months, 1 year

Secondary

Measure	Time frame
A better estimate of the reproducibility of standard clinical tests.	Day 1, 1 week, 6 months, 1 year

Outcome results